The aim of this study is to investigate the role of oral midodrine in the recovery of septic shock. The investigators hypothesize that the oral drug can reduce central line days and ICU length of stay.
The investigators aim to investigate the use of midodrine in the recovery phase of septic shock in a randomized control trial. The investigators hypothesize that midodrine use initiated after stabilization or improving intravenous vasopressor requirement will lead to decreased length of ICU stay and length of time that intravenous vasopressors are required. The investigators plan to enroll and consent patients at the onset of septic shock. Once IV vasopressor requirement is stabilized or decreasing, males and females will be randomized in 1:1 fashion to receive either standard clinical care or standard clinical care plus oral midodrine. The investigators will analyze length of stay in the ICU, time on vasopressors, time needing a central line, and hospital length of stay.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Midodrine will be given to treatment arm as enteral medication
Patients in the control arm will receive standard of care for septic shock
University of Virginia
Charlottesville, Virginia, United States
ICU free days
ICU free days from first 28 days
Time frame: 28 days
Central venous catheter free days
Time frame: 28 days
IV vasopressor free days
Time frame: 28 days
Hospital length of stay
Time frame: up to 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.